Shares of Pharmasset (VRUS) shoot up 8.4% premarket after Morgan Stanley reiterates an Overweight rating after taking in the results of a study on the firm's liver disease treatment. The company took a hit Friday, down 11.9%, after rival Inhibitex (INHX) hit a home run with positive data from its hepatitis C drug trial.
Shares of Pharmasset (VRUS) shoot up 8.4% premarket after Morgan Stanley reiterates an...
From other sites
Video at CNBC.com (Mon, 12:06PM)
Video at CNBC.com (Mon, 12:00PM)
Video at CNBC.com (Thu, 12:00PM)
Video at CNBC.com (Jul 15, 2016)
Video at CNBC.com (Jul 12, 2016)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs